Barinthus Biotherapeutics (BRNS) Research & Development (2020 - 2026)

Barinthus Biotherapeutics has reported Research & Development for 7 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 56.66% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $20.9 million (down 47.04% YoY), and the FY2025 full-year result was $25.6 million, down 39.47% from the prior year.
• Research & Development for Q1 2026 stood at $3.6 million, down from $3.9 million in the prior quarter.
• The five-year high for Research & Development was $15.1 million in Q3 2023, with the low at $3.6 million in Q1 2026.
• Historically, Research & Development has averaged $9.3 million across 5 years, with a median of $9.7 million in 2022.
• Annual changes were most pronounced in 2022 — Research & Development jumped 132.13% — and 2026, when it tumbled 56.66%.
• Barinthus Biotherapeutics' Research & Development stood at $12.2 million in 2022, then tumbled by 47.7% to $6.4 million in 2023, then surged by 30.39% to $8.3 million in 2024, then sank by 52.7% to $3.9 million in 2025, then fell by 8.6% to $3.6 million in 2026.
• The last three Research & Development figures came in at $3.6 million (Q1 2026), $3.9 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.